AlcoChange is intended to increase abstinence and reduce alcohol use in patients with alcohol related liver diseases (ARLD) by providing behavioural therapy based on CyberLiver Behaviour Change (CBC) Model that is designed from a blend of principles from various behaviour change theories in the design of Digital Behaviour Change Techniques (DBCTs), Digital Behaviour Change Interventions (DBCI’s) and Personalised Digital Behaviour Change Notifications (DBCN’s).
AlcoChange is intended to provide behavioural therapy as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician. AlcoChange is indicated as a 90 days prescription-only treatment for patients with Alcohol Related Liver Disease.